A next generation CRISPR diagnostic tool to survey drug resistance in Human African **Trypanosomiasis.** Authors and affiliations Elena Pérez Antón¹, Annick Dujeancourt-Henry¹, Brice Rotureau^{2,3*}, Lucy Glover^{1*} ¹Trypanosome Molecular Biology Unit, Institut Pasteur, Université de Paris, Paris, France ²Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1201, Institut Pasteur, Université de Paris, Paris, France ³Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea *Corresponding authors: lucy.glover@pasteur.fr; brice.rotureau@pasteur.fr Keywords Human African trypanosomiasis, Trypanosoma brucei gambiense, SHERLOCK, crRNA, Cas13a, drug-resistance, acoziborole, melarsoprol, pentamidine.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Abstract

The WHO aims to eliminate the gambiense form of human African trypanosomiasis (HAT) by 33 34 2030. With the decline of reported cases, maintaining efficient epidemiological surveillance is 35 essential, including the emergence of drug-resistant strains. We have developed new highly 36 specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing 37 (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are 38 already circulating, such as the AQP2/3(814) chimera providing resistance to pentamidine and 39 melarsoprol, or (2) could emerge, such as TbCPSF3 (N²³²H), associated to acoziborole resistance in lab conditions. The melarsoprol - pentamidineAQP2/3(814) SHERLOCK assay 40 detected RNA from both cultured parasites and field isolated strains from gHAT patients in 41 42 relapse following treatment. The acoziborole CPSF3(SNV)SHERLOCK assay discriminated 43 between wild-type CPSF3 RNA and CPSF3 with a single A-C mutation that confers resistance 44 to acoziborole in vitro.

45

46 Introduction

Human African trypanosomiasis (HAT), or sleeping sickness, is one of the 21 conditions 47 48 identified as a neglected tropical diseases by the World Health Organization (WHO)¹. Caused 49 by an infection with the extracellular protozoan parasite *Trypanosoma (T) brucei (b) gambiense* 50 (gHAT) in West and Central Africa or T. b. rhodesiense (rHAT) in East and Southern Africa. 51 HAT infections follow a typical clinical pattern, initiating with intermittent fever and 52 lymphadenopathy during a first step of blood and lymph infection (stage 1) and advancing to 53 severe neurological symptoms when the parasites invade the cerebrospinal fluid (stage 2), and 54 ultimately death if untreated. The major difference in disease progression between T. b. 55 gambiense and T. b. rhodesiense is that the former is chronic lasting over several months to 56 years and the latter acute, lasting for several weeks. There is currently no prophylactic drug available for HAT, the approved chemotherapies depend on the parasite species and the stage 57 58 of the disease¹. For gHAT, children under the age of 6 or less than 20 kg are, as a first choice, 59 treated with pentamidine for stage 1 or NECT for stage 2. Patients older than 6 years old and 60 more than 20 kgs are treated with fexinidazole at stage 1, or with fexinidazole (if white blood 61 cell count in the cerebrospinal fluid is lower than $100/\mu$ L) or NECT at stage 2². If relapse is 62 detected, patients are treated with NECT. For rHAT, children under the age of 6 or less than 20 63 kg are treated with suramin as a first choice for stage 1 or melarsoprol for stage 2, and if relapse

is seen, fexinidazole may be given for compassionate use². Patients older than 6 years old and 64 more than 20 kgs are treated with fexinidazole for both stage 1 and 2, yet if relapse is detected, 65 patients are treated with suramin or melarsoprol². Both suramin and pentamidine require 66 prolonged intravenous administration, melarsoprol causes encephalopathic syndrome that is 67 68 fatal in up to one in ten patients and NECT involves a long and complex dose regime with 69 intravenous effornithine alongside oral nifurtimox over the course of two weeks at hospital³. 70 These drugs present either with side effects or, are logistically challenging to administer. Accurate diagnosis and staging of the disease are key for the selection of the appropriate drug 71 72 treatment, but diagnosis is based on a tedious algorithm, including lumbar puncture as a 73 confirmatory test for the most advanced stage of gHAT⁴. The high toxicity of some of these 74 drugs, especially melarsoprol, as well as the complex administration of NECT make access to 75 treatment challenging and have prevented implementation of mass treatment as a method of combating the disease 5. 76

Fexinidazole was approved in 2019 by the European Medicines Agency ⁶, as a 10-day oral 77 78 treatment regime that must be taken with food for optimal absorption, yet with treatment 79 emergent adverse events such as vomiting and nausea increases the risk of non-compliance ^{5,7}. 80 Due to the high-risk of non-compliance leading to the ingestion of suboptimal curative doses, the possibility of relapse is of concern – especially as it may occur late, up to 24 months post-81 82 treatment ⁵, which could increase the risk of the emergence of drug-resistance. Resistance to fexinidaxole is readily generated under laboratory conditions⁸ and occurs through a similar 83 84 mechanism as that to nifurtimox, via mutation of the nitroreductase (NTR) gene⁸. Therefore, 85 there already exists the potential that previous use of nifurtimox in the field may have already 86 led to the emergence of fexinidazole resistant parasites ⁹. Fexinadazole is currently the only oral drug approved for treatment of both stage 1 and 2 gHAT and rHAT ^{2,5}. Drug resistance is not 87 88 uncommon in the treatment of HAT, melarsoprol resistance emerged as early as 1970 and was widespread by 1990^{10,11}, while resistance to both effornithine and nifurtimox can be generated 89 in vitro 3 . 90

In a context where the therapeutic arsenal for treating HAT is limited, the emergence of drug resistance is possible where a selective pressure to survive is applied to parasites, placing both existing and potential future drug treatments at risk. Pentamidine and melarsoprol share the same mechanism of entry into the parasite cell through the adenosine transporters and the aquaglyceroporin channels (AQPs) ^{10,12}. Among the three aquaglyceroporin genes of *T. brucei* (*TbAQP1-3*) ¹³, the deletion of the *AQP2* locus is related to the melarsoprol-pentamidine crossresistance in bloodstream-forms, increasing their effective concentrations (EC₅₀) by 2- to 15-

fold, respectively ¹². Several distinct mutations in the *AQP2-AQP3* genes have been associated with relapse of HAT after treatment with melarsoprol in patients from the Mbuji-Mayi region of the Democratic Republic of the Congo ^{14,15} and the Mundri county of South Sudan^{14,16}. One specific chimera identified, a chimera containing the first 813 bp from *AQP2* and the last 126 bp from *AQP3*, here termed AQP2/AQP3₍₈₁₄₎, ¹⁵, was associated with cross-reactivity to melarsoprol and pentamidine ¹⁴. Although not a frontline drug yet, acoziborole promises to be key in the efforts to eliminate

105 HAT. Currently in phase III clinical trials, acoziborole could be approved for the treatment of both stages of gHAT by 2026¹⁷, it is a single oral dose benzoxaborole derivative that shows 106 high efficacy and safety. Its approval could eliminate the need for routine lumbar puncture and 107 108 would allow the treatment of parasitology-negative suspects, as well as making treatment more accessible to patients living in remote areas ^{17,18}. The drug molecule binds to the active site of 109 the Cleavage and Polyadenylation Specificity Factor 3 (CPSF3), which is involved in 110 trypanosome mRNA processing ¹⁹, inhibits polypeptide translation and reduces endocytosis of 111 haptoglobin-hemoglobin²⁰. However, resistance to acoziborole can be generated *in vitro*, 112 113 through editing a single nucleotide in the CPSF3 sequence ²¹.

114 The CRISPR based diagnostic - Specific High-sensitivity Enzymatic Reporter unLOCKing (SHERLOCK) - first amplifies nucleic acid using recombinase polymerase amplification 115 116 (RPA), which is then combined with the Cas13a nuclease, for target recognition via specific 117 guides, and a fluorescent reporter linked to a quencher by nucleotides. Target sequence 118 recognition activates Cas13a's 'collateral effect' of promiscuous ribonuclease activity. So far, 119 SHERLOCK diagnostic assays have been developed for two protozoan parasites, African 120 trypanosomes²² and *Plasmodium*²³. SHERLOCK is capable of detecting a few attomoles (10⁻¹⁸ 121 moles) of nucleic acids in a sample and its specificity was demonstrated by distinguishing 122 between closely related Zika and dengue viruses in clinical isolates, or mutant strains with unique SNPs ²⁴⁻²⁶. Here, we developed highly specific SHERLOCK assays that allow detection 123 124 of specific drug-resistance associated mutations and that could be essential for epidemiological 125 surveillance in the context of gHAT elimination and rHAT control. 126

4

127 Methods

128 Trypanosome and RNA material

- 129*T. b. brucei* Lister 427 bloodstream form cells were cultured in HMI-11 medium with 10 %130foetal bovine serum (Sigma-Aldrich) at 37 °C with 5% CO2. RNA extraction was carried out131from culture harvest at $1x10^6$ cell/mL. RNA extraction of *T. b. brucei* cells, *T. b. gambiense*132cell pellets, and human embryonic kidney (HEK) 293T cells were carried using the RNeasy133Mini kit (Qiagen). Lyophilized RNA extracted from *T. b. brucei* edited CPSF3¹⁹ was134resuspended in nuclease-free water.
- 135

Species	Strain	Phenotype	Source	Ref
T. b. brucei	Wild type	-	in vitro	
T. b. brucei	AQP2/3 chimera	Resistance to melarsoprol	in vitro	15
T. b. brucei	CPFS3 A-C mutant	Resistance to acoziborole	in vitro	19
T. b. gambiense	Wild type	-	in vitro	
T. b. gambiense	163AT	Resistance to melarsoprol	Human	15
T. b. gambiense	348BT	Resistance to melarsoprol	Human	15
T. b. gambiense	MBA	AQP2/3 chimera – no resistance	Human	15
T. b. gambiense	40AT	Resistance to melarsoprol	Human	14,15
T. b. gambiense	349 AT	Resistance to melarsoprol	Human	14,15
T. b. gambiense	K03048	Resistance to melarsoprol	Human	14,16
T. b. gambiense	Wild type	-	Human	15

136 **Table 1: Trypanosome strains and isolates used in this study.**

137

138 LwCas13a enzyme expression and purification

139 The plasmid pC013-Twinstrep-SUMO-huLwCas13a (Addgene plasmid #90097) was used for the protein expression in *Escherichia coli* RosettaTM 2(DE3) pLysS competent cells ²⁵. The 140 protein expression and purification of Leptotrichia wadei Cas13a (LwCas13a) enzyme was 141 performed as described in²⁷ with slight modifications ²². TB medium was reconstituted by 142 143 adding 47.8 g of TB powder to a 1-L flask, adding 8 mL of 100% (wt/vol) glycerol. Cell pellet 144 was lysed with supplemented lysis buffer composed by 2 complete Ultra EDTA-free tablets 145 (Roche), 500 mM NaCl, 100 mg lysozyme and 125-625 ng Deoxyribonuclease I from bovine pancreas (Sigma) to each 100 mL of lysis buffer. The LwCas13a was storage in single-use 146 147 aliquots at -80°C to avoid freeze-thaw cycles.

148 Design of RPA primers and crRNA

149 RPA primer pairs were designed using NCBI Primer-BLAST ²⁸ using the custom parameters 150 specified in²⁷. For the wild-type CPSF3 SHERLOCK we use the reference sequence 151 XM_839191.1 (Tb927.4.1340). For targeting the chimeric AQP2/AQP3₍₈₁₄₎ the reference 152 sequence KF564935.1 (*T. b. gambiense* strain 40AT) was used. The RPA primers used in the 153 study are included in Supplementary Table 1. RPA forward primers include at the 5' end, the 154 T7 promoter sequence (5'-GAAATTAATACGACTCACTATAGGG-3') that allow *in vitro* 155 transcription of the amplified target by T7 polymerase.

The DNA templates used to generate the crRNAs consist of: 1) the target sequence (5'-3') which will be the variable region between crRNA, also known as the spacer (with variable lengths from 20 to 28 nt), followed by 2) the direct repeat template common to all *Lw*Cas13a crRNAs (5'-GTTTTAGTCCCCTTCGTTTTTGGGGGTAGTCTAGTCTAAATC-3'), followed by 3) the T7 promoter sequence at the 3' end (5'-CCCTATATAGTGAGTCGTATTAATTTC-3'), which will allow *in vitro* transcription of the guides. DNA templates used are listed in Supplementary Table 1. All of the oligonucleotides mentioned were synthesized by ThermoFisher.

163 In vitro transcription and purification of crRNAs

164 The crRNA synthesis was carried out using a DNA template and in vitro transcription mediated 165 by T7 polymerase according to manufacturer's instructions using the HiScribe[™] T7 Ouick 166 High Yield RNA Synthesis Kit (NEB), as previously described ²⁷. Briefly, we first annealed 167 the crRNA DNA template and T7-3G oligonucleotide (5'-GAAATTAATACGACTCACTATAGGG-3') by denaturation for 5 min followed by slow 168 169 cooling ²². After in vitro transcription, the crRNAs were purified using magnetic beads 170 (Agencourt RNAClean XP) and stored at 300 ng/µL in single-use aliquots at -80°C to avoid 171 freeze-thaw cycles.

172 SHERLOCK assay

The Specific High Sensitivity Enzymatic Reporter unLOCKing (SHERLOCK) assay was performed as described in²⁷. The SHERLOCK reaction is a combination of a pre-amplification method by a reverse transcription (RT) recombinase polymerase amplification (RPA)²⁹ and a specific RNA-target recognition by Cas13-CRISPR RNA-guide (crRNA) machinery (Abudayyeh et al., 2016). The RT-RPA was carried out using the TwistAmp Basic kit (TwistDx) following manufacturer's instructions for 45 min at 42 °C as described by ²². The amplification step is followed by simultaneous *in vitro* transcription of the amplified target by

180 T7 polymerase (Biosearch technology) and detection of the LwCas13a-crRNA using the same condition as described by ²². For this purpose, 4 µL of the RT-RPA product of each replicate 181 182 was mixed with the following components in the following concentrations: 20 mM HEPES pH 183 6. 5, 9 mM MgCl2, 1 mM rNTP mix (NEB), 40 nM of LwCas13a, 2 U of Murine RNase 184 inhibitor (NEB), 25 U of NxGen T7 RNA Polymerase (Biosearch technology), 25 nM of 185 crRNA and 125 nM of RNaseAlert probe V2 (Invitrogen), in a final volume of 80 µL. The 186 reaction was performed in 384-well plates, F-bottom, µClear bottom (Greiner) incubated at 37 187 °C in a TECAN plate reader (INFINITE F200 PRO M PLEX), in which 20 µL x 3 of each 188 replicate reaction was distributed. Fluorescence measurements were collected every 10 minutes 189 up to 3 hours. All SHERLOCK reactions were performed in triplicate and three fluorescence 190 measurements were taken from each replicate. A negative control template (NCT) was added 191 in parallel to each independent assay by supplementation nuclease-free water as input.

192 **Statistical analysis**

193 The fluorescence intensity values obtained from the TECAN plate reader were analysed using 194 Excel. For each triplicate reaction at each timepoint, the mean fluorescence intensity value was 195 divided by the mean of the fluorescence intensity value of the NCT at the same timepoint, to 196 obtain the fold-change over background fluorescence. The formula used is as follows:

- 197
- 198

Fold – change over background fluorescence • •

199 =	Mean fluorescence intensity of a triplicate sample reaction at time (x	
	Mean fluorescence intensity of the triplicate NCT at time (x)	

200

201 The graphs and statistical analysis were performed using GraphPad Prism (version 9.3.1) 202 software. The Shapiro-Wilk normality test was performed to evaluate the type of data 203 distribution. The non-parametric Mann-Whitney U test or the parametric bilateral unpaired t-204 test, with Welch's correction, according to the data distribution results, were used for the 205 statistical comparison with 95% confidence interval. For multiple comparisons, we applied the two-stage linear step-up procedure ³⁰. Multiple sequence alignments were performed using 206 207 Clustal Omega³¹.

208

209 **Results**

210 Selection of SHERLOCK targets to detect the AQP2/AQP3₍₈₁₄₎ chimera.

211 We adapted our SHERLOCK4HAT ²² workflow for the detection of markers of resistance to 212 melarsoprol through the formation of an AQP2/3 chimera (Figure 1A). The AQP2/3₍₈₁₄₎ chimera 213 independently arose in two distinct HAT foci to currently made up 31.7 % of all known 214 melarsoprol resistant HAT infections ^{14,15}. The RPA forward primer amplified from nucleotide 215 position 705 of the AQP2 sequence, and the RPA reverse primer from position 841, which was 216 specific to the region AQP3 sequence of the chimera (Figure 1B). The sequences of the wild type (WT) AQP2 and AQP3 (Tb927.10.14170, Tb927.10.14160, respectively) and that of the 217 218 AOP2/3(814) chimera (KF564931.1) were aligned to select non-homologous regions between 219 AOP2 and AOP3 genes for the new primers binding sites (Figure 1B). The crRNA guides were 220 designed to target the region of the $AOP2/3_{(814)}$ chimera that was analogous to AOP2 (Figure 221 1B). We evaluated three crRNA for the ability to discriminate between RNAs extracted from 222 in vitro derived cells where both AOP2 and AOP3 were knocked out and the AOP2/3(814) chimera was expressed from the rRNA intergenic region ³², and from wild type *T. b. gambiense* 223 224 or T. b. brucei cells (Figure 1C). The three crRNAs specifically detected the cells expressing 225 the $AQP2/3_{(814)}$ chimera and did not cross-react with the WT trypanosomes or human cells

226 (Figure 1C).

227 The AQP2/AQP3₍₈₁₄₎-specific SHERLOCK assay can be used to identify samples from 228 cases of HAT relapses.

229 After demonstrating that the AQP2/AQP3₍₈₁₄₎-specific SHERLOCK assay was able to detect 230 RNA from in vitro modified cells, we wanted to investigate whether it could also detect 231 AQP2/AQP3₍₈₁₄₎-chimeric RNAs of parasites isolated from patients, from two geographically 232 distinct locations, showing relapses following treatment with melarsoprol in the Mbuji-Mayi 233 region of the Democratic Republic of the Congo and Mundri County in South Sudan (Figure 2A), which have been associated with mutations in the AOP2/3 genes¹⁴⁻¹⁶ (Figure 2B). We 234 235 tested 4 isolates: (1) a WT strain from a patient infected with T. b. gambiense with no mutation 236 in the AQP2/3 locus and no relapse; (2) the 163AT, 40AT, 349AT and K03048 strains from 237 patients with HAT relapse infected with T. b. gambiense bearing the AQP2/AQP3(814) 238 mutation¹⁴⁻¹⁶; (3) the MBA strain from a patient with unknown treatment outcome, infected 239 with T. b. gambiense containing an AQP2/3 chimera with the first 677 bp from AQP2, 202 bp of AQP3 and the last 60 bp from AQP2, termed as AQP2/3(678-880); and the 348BT strain 240 241 isolated from a cured patient that contains both $AOP2/3_{(814)}$ and $AOP2/3_{(880)}$ (first 879 bp

from AQP2, a point mutation at T869C and the last 60 bp from AQP3) chimeras (Figure 2B) 243 ¹⁵.

244 The sequences of the wild type AQP2 and 3, the $AOP2/3_{(814)}$ chimera (KF564931.1), 245 AQP2/3(880) (KM282050) and AQP2/3(678-880) (KM282034) were aligned to select non-246 homologous regions between AQP2 and AQP3 genes to design a second RPA primer pair 247 (Figure 2B, Supplementary table 1): the selected RPA forward primer amplified from nucleotide position 730 of the AQP2 sequence, and the RPA reverse primer from position 829 248 249 of the chimera sequence corresponding to the AQP3 sequence. Our crRNA guides should not 250 target the AOP2/3(880) (KM282050) or AOP2/3(678-880) (KM282034) chimeras (Figure 2B and 251 C). We first screened the samples using two pairs of RPA primer and two crRNA guides 252 (Supplementary figure 1A). The crRNA2 and RPA primer pair 1 were selected to assess the 253 samples and this SHERLOCK assay was shown to accurately discriminate between patient 254 samples that contained the $AOP2/3_{(814)}$ chimera or not (Figure 2D). As expected, the 163AT, 40AT, 349AT and 348 BT samples showed a robust signal in the SHERLOCK AQP2/3(814) 255 256 assay. The K03048 sample from South Sudan scored as positive in the assay, yet it showed a 257 lower fold-change, likely because the amount of RNA extracted from this sample was low 258 (Figure 2D). These results confirm that the SHERLOCK AOP2/3(814) assay can detect the 259 specific mutation associated with melarsoprol resistance from patient samples.

260 SHERLOCK detection of a single nucleotide variant in the CPSF3 gene.

261 Taking advantage of the specificity of SHERLOCK, we developed an assay that can 262 discriminate between the WT and the in vitro derived single nucleotide variant (SNV) of the CPSF3 gene (CPSF3_(SNV), accession number XM 839191: N²³²H, AAT-CAT), hereon referred 263 264 to as CPSF3_(SNV) which confers resistance to acoziborole ^{19,33}. We first screened RPA primer 265 pairs that were either 30 nt or 25 nt long (Supplementary figure 1B) and designed to amplify 266 the region containing the SNV. The RPA primer pair target amplification was assessed using 267 four different crRNA guides specific for the detection of CPSF3_(SNV). We observed higher fold-268 change values with the 30 nt RPA primer pair as compared to the 25 nt primer pair 269 (Supplementary Figure 1B). Therefore, we selected the long RPA primer pair for subsequent 270 optimization of the SHERLOCK assay.

Then, 12 crRNA guides were screened for detection of the $CPSF3_{(SNV)}$. We designed crRNAs using the following criteria: 1) setting the SNV complementary base at position 3 (counting from the 3' end of the crRNA) and the artificial mismatch (if any) at position 5; and 2) setting

the SNV complementary base at position 6 and the mismatch (if any) at position 4^{23,25,34} (Figure 274 275 3A). In addition, we designed crRNAs with spacer lengths shorter than described as optimal for LwCas13a (28 nt, ²⁷). Indeed, reducing the spacer length to a maximum of 20 nt reduced the 276 277 enzyme activity but maintained, or even improved, its ability to discriminate single mismatches by reducing background fluorescence in the off-target sample ^{25,34,35} (Figure 3B). Finally, since 278 279 consecutive double substitutions in the spacer have been described as effective in the loss of 280 collateral cleavage activity of the Cas13a enzyme ³⁵, we also evaluated the efficacy of placing the synthetic mismatch adjacent to our SNV, in order to generate a double mismatch in the off-281 282 target sequence (Figure 3B).

283 The crRNAs designed to detect the SNV at position 3 showed lower fluorescence emission and 284 were undetectable when using the crRNAs with a spacer length of 20 or 23 nt (Figure 3B). In contrast, the crRNAs detecting the SNV at position 6 gave high fluorescence intensity values 285 286 with both WT and CPSF3(SNV). The fluorescence was reduced only when the length of the spacer 287 was limited to 20 nt (Figure 3B). The best performing crRNA guide contained the SNV 288 complementary base at position 6 and a synthetic mismatch at position 4, with a spacer length of 20 nt (Figure 3B). We then evaluated whether the nucleotide selected as the artificial 289 290 mismatch could improve the specificity of the SHERLOCK CPSF3(SNV) assay. We selected the 291 best candidate obtained in the first screening (Figure 3B), which used an uracil (U) as the 292 mismatch (Figure 4A), as well as two other crRNAs, one using cytosine (Figure 4B) and the 293 other guanine (Figure 4C) as the artificial mismatch. Using either an uracil or a guanine base 294 as mismatch, the SHERLOCK assays showed statistically significant difference in fluorescence 295 intensity when comparing total RNAs from CPSF3_(SNV) to WT RNA (Figure 4A and C). Using a guanine, the fluorescence from the off-target (WT) sequence was reduced to near background 296 297 (Figure 4C). These data show that the SHERLOCK assay can be used to detect SNV in *T. brucei* 298 cells resistant to acoziborole.

299 **Discussion**

Here we describe the development of new drug resistance SHERLOCK assays for HAT that could be used for epidemiological surveillance. There are currently no molecular diagnostics that can screen for emerging drug resistance in HAT patients, yet resistance to all the currently approved drugs used to treat HAT has been detected either in the field or can be generated in a laboratory. The two SHERLOCK assays described here can distinguish WT and either gene chimera's or SNV targets. As an RNA diagnostic, these SHERLOCK assays can be used to

306 screen patients presenting relapse after treatment and could be used to discriminate between 307 relapse or reinfection, which is critical for adapting drug treatment.

308

309 Although no longer used for the treatment of gHAT, melarsoprol is still recommended by the 310 WHO for treatment of rHAT at stage 2 in children or as a second option in adults. Unlike gHAT, 311 rHAT is an acute infection, with disease progression taking from weeks to months. Resistance 312 to melarsoprol would, therefore, represent a significant obstacle to control rHAT. In this study, we have developed a SHERLOCK assay targeting mutations in the AQP2/3 locus that were 313 314 initially identified in circulating parasites by sequencing samples from patients with relapses 315 after treatment^{14,15}. Our high-throughput AQP2/3₍₈₁₄₎ SHERLOCK assay detected all parasites 316 involved in relapses without cross reactivity and could be quickly implemented in reference 317 labs in the field. One limitation of using SHERLOCK for detecting drug resistance is the 318 intrinsic dependency of the method on prior knowledge of the gene mutations for the design of 319 RPA primers and crRNAs. However, by using our existing SHERLOCK4HAT workflow²², 320 the assay could rapidly be adapted and implemented once a mutation has been identified.

321

322 Acoziborole will likely become the next frontline drug for the treatment of gHAT to move towards elimination of the disease by 2030^{17,36}. Like for the other drugs used to treat HAT, 323 324 resistance to acoziborole can be generated in the laboratory through a single point mutation in the CPSF3 gene ^{19,33}. Several SHERLOCK assays have been developed to detect SNV ^{23,25,34}, 325 326 and LwCas13a, used in this study, is capable of tolerating mismatches, yet with a reduced cutting efficient ³⁷. This could be ameliorated by optimising the crRNA guide length, the 327 328 positioning of the mismatch, and/or the Cas13 variant used ³⁴. In our *CPSF3*(SNV) SHERLOCK 329 assay, we found that the most efficient combination was a 20 nt crRNA, the SNV at position 6 330 and the synthetic mismatch at position 4. Within the $CPSF3_{(SNV)}$ SHERLOCK assay, there is 331 still scope for optimisation to improve the specificity of the assay and which Cas13 variant 332 could provide better on vs. off target discrimination. In our assays, the nucleotide selected for 333 the mismatch had the most profound effect on the sensitivity of the assay, especially in the 334 discrimination between on and off target. Here, the use of a guanine as the mismatch at position 335 4 showed the best discrimination between the two targets. Should resistance arise from a SNV 336 or a chimeric gene formation, fully exploiting how the Cas13a-RNA complex is formed will be key to developing a robust assay for epidemiological surveillance. 337

338 This study demonstrates the versatility of the SHERLOCK technology to detect known genetic 339 modifications directly associated to drug resistance, using existing workflows. The major 340 challenge to develop a SHERLOCK assay is that the targeted genetic mutation must be both 341 known and stable. However, for rHAT treatment with melarsoprol, we showed that known 342 resistance mechanisms through the formation of chimeras, that have arisen in geographically 343 separated regions, are suitable targets for SHERLOCK. Given the adaptability of SHERLOCK, generating a HAT antimicrobial resistance toolbox will be an invaluable asset for 344 345 epidemiological surveillance to screen any cases of relapse. This will be critical not only to 346 track the incidence of resistance, but also for subsequent selection of the most individually 347 adapted drug treatment.

348

349 Abbreviations

- 350 AQP: Aquaglyceroporin
- 351 CPSF3: Cleavage and polyadenylation specific factor 3
- 352 CRISPR: Clustered regularly interspaced short palindromic repeats
- 353 crRNA: CRISPR RNA
- 354 HAT: Human African trypanosomiasis
- 355 HEK: Human embryonic kidney
- 356 LwCas13a: Leptotrichia wadei CRISPR-associated protein 13 a
- 357 NCT: Negative control template
- 358 NECT: Nifurtimox- effornithine combination therapy
- 359 PAM: Protospacer adjacent motif

- 360 RPA: Recombinase polymerase amplification
- 361 RT: Reverse transcription
- 362 SHERLOCK: Specific High-sensitivity Enzymatic Reporter unlocking
- 363 SNV: Single nucleotide variant
- 364 SUMO: Small ubiquitin-like modifier
- 365 WT: Wild-type

366 Acknowledgments

The authors acknowledge the support of the researchers who made this work possible by providing the necessary genetic materials: *T. b. gambiense* ELIANE cell pellets were provided

369 by Pr. Annette MacLeod (University of Glasgow, UK); lyophilized RNA extracted from

370 CPSF3-edited T. b. brucei were provided by Pr. David Horn (University of Dundee, UK); RNA

371 from chimeric AQP2/AQP3 T. b. gambiense isolates were provided by Dr. Nick Van Reet

372 (Institute of Tropical Medicine, Antwerp) and Pr. Pascal Maeser (Swiss Tropical and Public

373 Health Institute, Switzerland).

374 Author contribution

375 EPA, BR and LG conceived and designed the experiments. EPA and ADH performed the

experiments. EPA, BR and LG analysed the data. BR and LG contributed reagents, materialsand analysis tools. EPA, BR and LG wrote the paper.

378 Funding

- 379 This project has received funding from the Agence Nationale pour la Recherche (ANR-PRC
- 380 2021 SherPa). The funders had no role in study design, data collection and analysis, decision
- 381 to publish, or preparation of the manuscript.

382 Figures and Tables

383

384 Figure 1. Detection of the AQP2/3(814) chimera by SHERLOCK. (A) Schematic of the AQP2 385 and AQP3 wild type locus (left) and the AQP2/AQP3(814) chimera (right). The RPA primers (arrows) and crRNA target (RNA guide) regions for detection of the AQP2/AQP3(814) chimera 386 387 are shown. (B) Alignments of the chimera AQP2/AQP3(814) (KF564931.1), WT AQP2 388 (Tb927.10.14170) and AQP3 (Tb927.10.14160) sequences are shown with the non-389 homologous regions highlighted in gray. (C) crRNA screening for the detection of the 390 AOP2/AOP3₍₈₁₄₎ chimera using RNA from in vitro derived AOP2/AOP3₍₈₁₄₎, WT T.b.b. (T. b. 391 brucei), WT T.b.g. (T. b. gambiense), and human embryonic kidney (HEK) cells. RNA input at 392 1 ng/ μ L. Asterisk represents p values at (*) p<0.001 and (**) p<0.0001.

393

394 Figure 2. Evaluation of the AQP2/AQP3(814) SHERLOCK assay on isolates from HAT 395 patients with relapses associated with the formation of AQP2/3 chimeras. (A) Map showing 396 the regions where patient with relapse after treatment was detected (B) Schematics of the AOP2 397 and AQP3 loci in 4 different strains isolated from patients in the DRC (WT, 163AT, MBA and 398 348BT) and South Sudan (K03048). The RPA primers (arrows) and crRNA target (RNA guide) 399 regions for detection of the AOP2/AOP3(814) chimera are shown. (C) Alignments of the WT AOP2 (Tb927.10.14170) and AQP3 (Tb927.10.14160); AQP2/AQP3₍₈₁₄₎ (KF564931.1); 400 401 AQP2/3(880) (KM282050) and AQP2/3(678-880) (KM282034) sequences are shown with the non-402 homologous regions highlighted in gray. (D) Kinetic representation of the Cas13a reaction 403 using the APQ2/3₍₈₁₄₎-specific SHERLOCK assay testing the different RNAs extracted from 404 the 6 strains isolated from DRC patients (163AT, 348BT, 40AT, 349AT, MBA and WT) and 405 one strain form South Sudan (K03048) (left graph). Representation of the fold-change over 406 background fluorescence after 180 min (time point taken indicated by black arrow in kinetic 407 plot) of Cas13a reaction using the APQ2/3(814)-specific SHERLOCK assay analysing the RNAs 408 from the different isolated strains (right graph).

409

410 Figure 3. Optimization of a SHERLOCK assay for the detection of CPSF3 single

411 **nucleotide variant (SNV)**. (A) Schematic of the crRNAs design for the detection of the single

412 nucleotide variant (SNV) in the *CPSF3* gene. Position of the SNV in red and the inclusion of

413 the synthetic mismatch along the crRNA spacer in green. (B) Screening of crRNAs designed

414 for the detection of *CPSF3*-edited cells. The target sequence of each crRNA is indicated, as

415 well as the PFS in brackets. crRNAs used for detection of the CPSF3(SNV): 1) SNV fixed at 416 position 3, and 2) SNV fixed at position 6. SNV is in underlined and bold character, and 417 synthetic mismatch is in underlined, bold and italicized character. crRNAs with different spacer 418 lengths were evaluated (20, 23 and 27 nt). The heat map shows the fold change over background 419 fluorescence intensity values collected at time zero and after 3 h of LwCas13a detection 420 reaction. G, guanine; A, adenine; U, uridine; C, cytosine; PFS, protospacer flanking site; 421 TbCPSF3, Trypanosoma brucei gambiense cleavage and polyadenylation factor 3; WT, wild 422 type.

423

Figure 4. Evaluation of selected nucleotides used as synthetic mismatches in the 424 425 **CPSF3**(SNV) SHERLOCK assay. Kinetic representation of LwCas13a reaction for the selected 426 base for the synthetic mismatch at nt 4: uracil (A), guanine (B) or cytosine (C). The fold-change 427 over background fluorescence was indicated at different time points of the LwCas13a reaction. 428 Results from WT cells are shown with open circles and those from edited CPSF3(SNV) cells with 429 red dots. Box-plots represent fold-change over background fluorescence intensity values using 430 RNA from WT cells (gray box-plots) or RNA from CPSF3_(SNV)-edited cells (red box-plots) at 431 the selected time-point, here indicated by a red arrow in each kinetic plot. RNA input at 5 ng/ μ L. The p values are represented by asterisks as follows: p<0.05 (*), p<0.01 (**) and p<0.001 (***). 432 433

Supplementary Figure 1. RPA primer screening. (A) Representation of the results obtained 434 435 in the screening of RPA primers (1 and 2) and crRNAs (2 and 3) for the AQP2/3(814)-specific 436 SHERLOCK assay using as input the different RNAs from the extraction of strains isolated 437 from gHAT patients that contains the AQP2/3₍₈₁₄₎ (163AT and 384BT) or not (MBA and WT). 438 (B) Evaluation of the pairs of RPA longer length primers (30 nt) and shorter length primers (25 439 nt) by SHERLOCK assay using four potential crRNAs (1 to 4) specific for the detection of 440 genetic material of *CPSF3*_(SNV)-edited cells. The data were represented as the fold-change over 441 background fluorescence, taking the values obtained after 60 min of LwCas13a detection 442 reaction.

443

444 Supplementary Table 1. RPA primers and crRNA templates used in this study.

445

446 **References**


medRxiv preprint doi: https://doi.org/10.1101/2024.09.15.24313552; this version posted September 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 447
- 448 1. WHO. Global report on neglected tropical diseases 2024. 2024.
- 449 2. WHO. Guidelines
- 450 for the treatment of human African trypanosomiasis. *WHO* 2024.
- 451 3. Dickie EA, Giordani F, Gould MK, et al. New Drugs for Human African 452 Trypanosomiasis: A Twenty First Century Success Story. *Trop Med Infect Dis* 2020; **5**(1).
- 453 4. Checchi F, Chappuis F, Karunakara U, Priotto G, Chandramohan D. Accuracy of five
- 454 algorithms to diagnose gambiense human African trypanosomiasis. *PLoS Negl Trop Dis* 2011;
 455 5(7): e1233.
- 456 5. Lindner AK, Lejon V, Chappuis F, et al. New WHO guidelines for treatment of 457 gambiense human African trypanosomiasis including fexinidazole: substantial changes for 458 clinical practice. *Lancet Infect Dis* 2020; **20**(2): e38-e46.
- 459 6. Deeks ED. Fexinidazole: First Global Approval. Drugs 2019; 79(2): 215-20.
- 460 7. Pelfrene E, Harvey Allchurch M, Ntamabyaliro N, et al. The European Medicines
 461 Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. *PLoS Negl*462 *Trop Dis* 2019; **13**(6): e0007381.
- 463 8. Wyllie S, Foth BJ, Kelner A, Sokolova AY, Berriman M, Fairlamb AH.
 464 Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei. *J Antimicrob*465 *Chemother* 2016; 71(3): 625-34.
- 466 9. Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E. Drug resistance in
 467 human African trypanosomiasis. *Future Microbiol* 2011; 6(9): 1037-47.
- 468 10. Baker N, de Koning HP, Maser P, Horn D. Drug resistance in African trypanosomiasis:
 469 the melarsoprol and pentamidine story. *Trends Parasitol* 2013; 29(3): 110-8.
- 470 11. Fairlamb AH, Horn D. Melarsoprol Resistance in African Trypanosomiasis. *Trends*471 *Parasitol* 2018; **34**(6): 481-92.
- 472 12. Baker N, Glover L, Munday JC, et al. Aquaglyceroporin 2 controls susceptibility to
 473 melarsoprol and pentamidine in African trypanosomes. *Proc Natl Acad Sci U S A* 2012;
 474 109(27): 10996-1001.
- 475 13. Bassarak B, Uzcategui NL, Schonfeld C, Duszenko M. Functional characterization of
 476 three aquaglyceroporins from Trypanosoma brucei in osmoregulation and glycerol transport.
 477 *Cell Physiol Biochem* 2011; 27(3-4): 411-20.
- 478 14. Graf FE, Ludin P, Wenzler T, et al. Aquaporin 2 mutations in Trypanosoma brucei
 479 gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
 480 *PLoS Negl Trop Dis* 2013; 7(10): e2475.
- 481 15. Pyana Pati P, Van Reet N, Mumba Ngoyi D, Ngay Lukusa I, Karhemere Bin Shamamba
 482 S, Buscher P. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from
- 483 cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
 484 *PLoS Negl Trop Dis* 2014; 8(10): e3212.
- 485 16. Maina NW, Oberle M, Otieno C, et al. Isolation and propagation of Trypanosoma brucei
 486 gambiense from sleeping sickness patients in south Sudan. *Trans R Soc Trop Med Hyg* 2007;
 487 101(6): 540-6.
- 488 17. Betu Kumeso VK, Kalonji WM, Rembry S, et al. Efficacy and safety of acoziborole in
 489 patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a
 490 multicentre, open-label, single-arm, phase 2/3 trial. *Lancet Infect Dis* 2023; 23(4): 463-70.
- 491 18. Tarral A, Hovsepian L, Duvauchelle T, et al. Determination of the Optimal Single Dose
- 492 Treatment for Acoziborole, a Novel Drug for the Treatment of Human African
- 493 Trypanosomiasis: First-in-Human Study. *Clin Pharmacokinet* 2023; **62**(3): 481-91.
- 494 19. Wall RJ, Rico E, Lukac I, et al. Clinical and veterinary trypanocidal benzoxaboroles
 495 target CPSF3. *Proc Natl Acad Sci U S A* 2018; 115(38): 9616-21.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.15.24313552; this version posted September 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 496 20. Sharma A, Cipriano M, Ferrins L, Hajduk SL, Mensa-Wilmot K. Hypothesis-generating 497 proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African 498 Trypanosome. *iScience* 2022; **25**(11): 105302.
- 499 Kovarova J, Novotna M, Faria J, et al. CRISPR/Cas9-based precision tagging of 21. 500 essential genes in bloodstream form African trypanosomes. Mol Biochem Parasitol 2022; 249: 501 111476.
- 502 22. Sima ND-H, A.; Perlaza, BL.; Ungeheuer, MN.; Rotureau, B.; Glover, L. 503 SHERLOCK4HAT: a CRISPR-based tool kit for diagnosis of Human African 504 Trypanosomiasis. *medRxiv* 2022.
- Cunningham CH, Hennelly CM, Lin JT, et al. A novel CRISPR-based malaria 505 23. 506 diagnostic capable of Plasmodium detection, species differentiation, and drug-resistance 507 genotyping. EBioMedicine 2021; 68: 103415.
- 508 24. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed 509 and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 2018; 510 **360**(6387): 439-44.
- 511 25. Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-512 Cas13a/C2c2. Science 2017; **356**(6336): 438-42.
- 513 Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using 26. 514 CRISPR-Cas13. Science 2018; 360(6387): 444-8.
- 515 Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic 27. acid detection with CRISPR nucleases. Nat Protoc 2019; 14(10): 2986-3012. 516
- 517 Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: 28.
- 518 a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 519 2012; 13: 134.
- 520 29. Piepenburg O, Williams CH, Stemple DL, Armes NA. DNA detection using 521 recombination proteins. PLoS Biol 2006; 4(7): e204.
- 522 Benjamini YaH, Y. Controlling the False Discovery Rate: a Practical and Powerful 30.
- 523 Approach to Multiple Testing. The Journal of the Royal Statistical Society, Series B (Statistical 524 Methodology) 1995; 57(1): 289-300.
- 525 Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein 31. 526 sequences. Protein Sci 2018; 27(1): 135-45.
- Graf FE, Baker N, Munday JC, de Koning HP, Horn D, Maser P. Chimerization at the 527 32.
- 528 AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical
- 529 Trypanosoma brucei gambiense isolates. Int J Parasitol Drugs Drug Resist 2015; 5(2): 65-8.
- 530 33. Altmann S, Rico E, Carvalho S, et al. Oligo targeting for profiling drug resistance 531 mutations in the parasitic trypanosomatids. *Nucleic Acids Res* 2022; **50**(14): e79.
- 532 Molina Vargas AM, Sinha S, Osborn R, et al. New design strategies for ultra-specific 34.
- 533 CRISPR-Cas13a-based RNA detection with single-nucleotide mismatch sensitivity. Nucleic
- 534 Acids Res 2024; **52**(2): 921-39.
- 535 Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-35. 536 Cas13. Nature 2017; 550(7675): 280-4.
- 537 Franco JR, Priotto G, Paone M, et al. The elimination of human African 36. 538 trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets. PLoS 539 *Negl Trop Dis* 2024; **18**(4): e0012111.
- 540 Mantena S, Pillai PP, Petros BA, et al. Model-directed generation of CRISPR-Cas13a 37. 541 guide RNAs designs artificial sequences that improve nucleic acid detection. bioRxiv 2023.
- 542 543










Figure 2




С

Sequence		Forward RPA Primer	crRNA target region	Reverse RPA Primer	
AQP2/3(814)] CTTAGCGTCTCCCCTTGCGATGAATCCC (T) [.		
AQP2/3 (880)	705	GTACGAAACGGTAGCTATTGGTGC [] CTTAGCGTCTCCCCTTGCGATGAATCCC (T) [.]CGGTGCGATCCTTCTCGGGGGGGGAAGTTT	841
AQP2/3 (678-880	,705	ACACGAGCCGTTGGCAGTTGGTGC[.]TTACTCAACGGGTTACGCAATAAATCCG(G)[.] CTCTTCTTTTCTTTATGGTGGGGAGGTGT	841
WT.AQP2	705	GTACGAAACGGTAGCTATTGGTGC[.] CTTAGCGTCTCCCCTTGCGATGAATCCC (T) [.]CGGTGCGATCCTTCTCGGGGGGGGAAGTTT	841
WT.AQP3	681	ACACGAGCCGTTGGCAGTTGGTGC[.] TTACTCAACGGGTTACGCAATAAATCCG (G) [.]CTCTTCTTTTCTTTATGGTGGGAAGGTGT	841

N: non-homologous region







UCAUUGCAGAGAGUACACAAGGU(A)-UUGCAGAGAGUACACAAGGIITA) UCAUUGCAGAGAGUACACUUG ACA<u>CU</u>UGGU(A) Time (min):

AUUCUCAUUGCAGAGAGUAGACAUGGU(A) AUUCUCAUUGCAGAGAGUACACAAGGU(A)-

SNVs in nt $6 \rightarrow$ synthetic mismatch in nt 4 or 5

UUGCAGAG

Short spacer



Fold Change over background fluorescence (a.u.)

10

5

Figure 4

